TMG Supplementation Dosing and Safety
For adults without homocystinuria, TMG supplementation lacks FDA approval and established clinical guidelines—it should not be routinely recommended outside of its approved indication for treating homocystinuria, where the standard dose is 6 grams daily in divided doses (3 grams twice daily). 1
FDA-Approved Indication and Dosing
TMG (trimethylglycine/betaine anhydrous) is FDA-approved specifically for homocystinuria treatment, not as a general supplement 1:
- Adults and children ≥3 years: 6 grams per day, divided as 3 grams twice daily 1
- Children <3 years: Start at 100 mg/kg/day (50 mg/kg twice daily), increase weekly by 50 mg/kg increments based on plasma homocysteine monitoring 1
- Administration: Dissolve in 4-6 ounces of water, juice, milk, or formula, or mix with food for immediate consumption 1
Critical Safety Concerns
The most serious risk is hypermethioninemia in patients with cystathionine beta-synthase (CBS) deficiency, which can lead to cerebral edema 1:
- Monitor plasma methionine concentrations in CBS deficiency patients
- Keep methionine levels below 1,000 micromol/L through dietary modification
- Reduce TMG dose if methionine becomes elevated 1
Common adverse effects (>2% incidence):
- Nausea
- Gastrointestinal distress 1
Monitoring Parameters
For patients on TMG for homocystinuria:
- Plasma homocysteine concentrations: Titrate dose until homocysteine is undetectable or minimally present 1
- Plasma methionine concentrations: Essential in CBS deficiency to prevent dangerous elevations 1
Clinical Context
The provided guidelines address diabetes, obesity, and chronic kidney disease nutrition but do not mention TMG supplementation 2, 3. There is no established role for TMG in these conditions based on current clinical practice guidelines. The 2013 endocrinology guidelines specifically note "insufficient evidence to support the routine use of antioxidants, chromium, magnesium, and/or vanadium" in diabetes patients, reflecting the general stance on unproven supplements 3.
No contraindications are listed in the FDA labeling 1, but this reflects the narrow approved indication rather than broad safety data for general supplementation use.